Scintilla Pharmaceuticals pipeline consists of two investigational product candidates spanning the interventional pain spectrum.
|Product||Indication||Preclinical||Phase I||Phase II||Phase III|
|SP-102||Lumbar Radiculopathy||Phase 2|
|RTX||Cancer Pain||Phase 1|
- Near term clinical milestones
- Worldwide commercial rights to all products
- Strong proprietary platform
These products are investigational and as such, have not been approved by the FDA or any regulatory authority.